Exchange-traded funds, or ETFs, streamline investing and make a diverse portfolio more accessible to everyone. You don’t have to meticulously analyze stocks and market trends on a daily basis to generate solid long-term…
Read moreInvestors looking to identify the best long-term stocks to buy should focus on companies with consistent earnings growth and strong financial health, not necessarily the latest futuristic headlines. Sure, it’s easy to understand…
Read moreHealthcare-focused SPAC Blue Water Acquisition IV prices $125 million IPO IPO Overview Blue Water Acquisition IV, a fourth blank check company led by the founder of Blue Water Venture Partners targeting healthcare and…
Read moreHong Kong industrial equipment supplier Pacipic Nexus IntelliTech Group files for a $23 million US IPO IPO Overview Pacipic Nexus IntelliTech Group, a Hong Kong-based supplier of industrial equipment for high-precision manufacturing, filed…
Read moreSingaporean consulting firm HAMA Intelligence increases shares offered by 20% ahead of $22 million US IPO IPO Overview HAMA Intelligence, a Singaporean accounting and business consulting firm, raised the proposed deal size for…
Read moreSmall modular reactor developer X-Energy files for an estimated $300 million IPO IPO Overview X-Energy, a developer of small modular reactors and producer of nuclear fuel, filed on Friday with the SEC to…
Read moreFinding high-quality investment opportunities among stocks priced under $10 is a challenge considering most companies with low stock prices have significant risks and uncertain futures. However, there are a handful of hidden gems…
Read moreYou can’t scroll through a financial news feed today without seeing a headline about a major market segment, be it tech or industrials, getting completely reshaped by artificial intelligence. And with the recent…
Read moreWhen times get tough on Wall Street, many investors turn to high-yield dividend ETFs. Exchange-traded funds provide a steady stream of income that isn’t dependent on buying low and selling high, and they…
Read moreIsrael-listed cell therapy biotech Bonus Biogroup sets terms for $15 million US IPO IPO Overview Bonus Biogroup, a Phase 2 Israeli biotech developing cell therapies for bone regeneration and respiratory indications, announced terms…
Read more